Literature DB >> 28848832

The COPD Pipeline, XXVI.

Nicholas Gross1.   

Abstract

Keywords:  3-D printing in lung disease; COPD drug development; COPD pipeline; cytisine; first-in-class; p38 MAP kinase inhibition

Year:  2015        PMID： 28848832      PMCID： PMC5556776          DOI： 10.15326/jcopdf.2.1.2014.0166

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN： 2372-952X


× No keyword cloud information.
  11 in total

1.  Bioresorbable airway splint created with a three-dimensional printer.

Authors:  David A Zopf; Scott J Hollister; Marc E Nelson; Richard G Ohye; Glenn E Green
Journal:  N Engl J Med       Date:  2013-05-23       Impact factor: 91.245

2.  The shape of things to come: 3D printing in medicine.

Authors:  Mark H Michalski; Joseph S Ross
Journal:  JAMA       Date:  2014-12-03       Impact factor: 56.272

3.  Smoking cessation drugs market.

Authors:  Basharut A Syed; Kritika Chaudhari
Journal:  Nat Rev Drug Discov       Date:  2013-02       Impact factor: 84.694

4.  P38 inhibition in COPD; cautious optimism.

Authors:  Dave Singh
Journal:  Thorax       Date:  2013-04-23       Impact factor: 9.139

5.  The COPD pipeline.

Authors:  Yasser Mushtaq
Journal:  Nat Rev Drug Discov       Date:  2014-03-14       Impact factor: 84.694

6.  An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease.

Authors:  David A Lomas; David A Lipson; Bruce E Miller; Lisa Willits; Oliver Keene; Helen Barnacle; Neil C Barnes; Ruth Tal-Singer
Journal:  J Clin Pharmacol       Date:  2011-11-16       Impact factor: 3.126

7.  Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial.

Authors:  Henrik Watz; Helen Barnacle; Benjamin F Hartley; Robert Chan
Journal:  Lancet Respir Med       Date:  2013-12-05       Impact factor: 30.700

8.  Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease.

Authors:  J Armstrong; C Harbron; S Lea; G Booth; P Cadden; K A Wreggett; D Singh
Journal:  J Pharmacol Exp Ther       Date:  2011-05-24       Impact factor: 4.030

9.  Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial.

Authors:  William MacNee; Richard J Allan; Ieuan Jones; Maria Cristina De Salvo; Lisa F Tan
Journal:  Thorax       Date:  2013-03-28       Impact factor: 9.139

Review 10.  What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.

Authors:  Joanna Leaviss; William Sullivan; Shijie Ren; Emma Everson-Hock; Matt Stevenson; John W Stevens; Mark Strong; Anna Cantrell
Journal:  Health Technol Assess       Date:  2014-05       Impact factor: 4.014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.